Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

HitGen and Nested Therapeutics Sign Research Service Agreement for DNA-Encoded Library

August 16, 2023

HitGen has entered into a research service agreement with Nested Therapeutics for use of HitGen’s DNA-encoded library for drug discovery.

Webcasts

Scale Up Considerations for Dry Powder Inhaler Manufacturing by Spray Drying

August 11, 2023

Webinar Date/Time: Thu, Sep 28, 2023 11:00 AM EDT

Overcoming Challenges to Formulation Development for Pediatric Medicines

August 03, 2023

The biggest hurdle is developing palatable formulations that are efficacious and patient friendly.

An Intelligent Drug Development Paradigm

August 03, 2023

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.

New Magic from mRNA

August 02, 2023

mRNA may be a modality whose chief advances are yet to come.

Exploring an Intelligent Drug Development Paradigm

August 02, 2023

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.

Drug Solutions Podcast: Innovations and Advances in Drug Dosage Forms

August 01, 2023

In this episode, David Tisi and Reenal Gandhi provide expert insights into advances and innovations changing the drug dosage form landscape.

Teva Pharmaceuticals and Alvotech Expand Existing Biosimilars Partnership

July 27, 2023

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

EMA Gives Positive Opinion on Two of Janssen’s Bispecific Antibodies

July 27, 2023

Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.

Crossbow Therapeutics Debuts with $80 Million in Series A Financing to Advance Antibody Therapeutics

July 24, 2023

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.